Pharmaceuticals News and Research

RSS

Vaccinations recommended for adults

Yearly vaccinations aren't just for kids any more. You probably heard a lot about a seasonal or H1N1 flu shot last fall, but you should know that a battery of other adult vaccinations might also become part of your health care routine. Pneumonia and shingles vaccines are preventive-care essentials for older adults, and meningitis and tetanus shots are now college rites of passage. Even the vaccines of childhood—measles, mumps and rubella, and whooping cough—are recommended for adults who missed out in their younger years.

19 May 2010

i3 completes acquisition of ChinaGate

i3, a global life sciences services company and subsidiary of Ingenix, has acquired ChinaGate, a contract research organization that provides product-development regulatory services for pharmaceutical, medical device and biotechnology companies looking to enter and access the Chinese market.

19 May 2010

TPP raises £9.6M to develop early-stage pre-clinical drug candidates

TPP Global Development, an innovative drug development company, announced today it has raised £9.6m which will be used to execute the Company's strategy to develop early-stage pre-clinical drug candidates.

19 May 2010

New multi-center follow-up study of NX-1207 for treatment of BPH to be completed

Nymox Pharmaceutical Corporation announced today that the Company is nearing completion of a new multi-center U.S. long-term follow-up study of NX-1207, its investigational drug for the treatment of benign prostatic hyperplasia.

19 May 2010

Opinions: Gender-based violence and HIV; AIDS vaccine; Global NTDs; Responses to NYT HIV/AIDS articles

"Gender-based violence is a world-wide pandemic and directly affects the spread of HIV/AIDS. Fear of violence limits the ability of women and girls to choose their partners; to find out about a partner's HIV status or disclose their own; and to get medical or counseling services," according to a U.S. government editorial in VOA News.

19 May 2010

BMJ News examines how drug resistance, access undermine malaria fight in Uganda, Cambodia

BMJ News looks at how lack of access to drugs and resistance are undermining the fight against malaria.

19 May 2010

Flibanserin benefits pre-menopausal women with Hypoactive Sexual Desire Disorder

Data from pivotal Phase III clinical trials demonstrate that a higher proportion of pre-menopausal women with Hypoactive Sexual Desire Disorder (HSDD) receiving flibanserin 100mg reported both an improvement in their condition and a meaningful benefit from their treatment, compared to placebo.

19 May 2010

Molecular Devices' foundational planar patch-clamp patent upheld by European Patent Office

Molecular Devices today announced that European Patent Office (EPO) has upheld Molecular Devices foundational planar patch-clamp patent (EP No 1 040 349 B1). The board will issue a written decision to this effect in the near future. The ruling will be the final determination of the EPO and cannot be appealed.

19 May 2010

PCMA releases statement on AARP's report on price increase in brand name prescriptions

The Pharmaceutical Care Management Association released the following statement on a new report from AARP that found that the price of brand name prescriptions most widely used by Medicare beneficiaries increased by 9.7 percent in the 12 months ending with March 2010 and was much higher than the rate of increase observed during any of the prior eight years

19 May 2010

RegeneRx Biopharmaceuticals prices underwritten public offering at $0.41 per unit

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company focused on the development of a novel therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair and regeneration in cardiovascular diseases, central nervous system injuries, ophthalmic indications and dermal wounds, announced the pricing of its previously announced underwritten public offering of 11,500,000 units of its securities at a public offering price of $0.41 per unit.

19 May 2010

AARP: Cost of brand name drugs rose 9.7% last year

"The AARP says that manufacturer prices for brand-name prescription drugs commonly used by people on Medicare rose 9.7% for the year ending in March — the biggest annual jump since the group started tracking prices in 2002," The Wall Street Journal Health Blog reports.

19 May 2010

Report released on pharmaceutical mail-back pilot program funded by EPA

Through a grant awarded by the U.S. Environmental Protection Agency (EPA), the University of Maine’s Center on Aging has completed the first statewide mail-back pilot program for managing pharmaceutical waste from consumers.

18 May 2010

GCS to acquire FASA for $637 million

Grupo Casa Saba, S.A.B. de C.V., and various Chilean legal entities that are controlled by Mr. José Codner Chijner, who is the final controller of Farmacias Ahumada S.A. announced that they have reached a definitive agreement under which GCS will acquire the control of FASA in a transaction valued at approximately US$637 million, including the assumption of US$162 million in estimated net debt as of March 31, 2010.

18 May 2010

Catalyst Pharmaceutical Partners first-quarter net loss decreases to $0.06 per basic and diluted share

Catalyst Pharmaceutical Partners, Inc. today announced its financial results for the three month period ended March 31, 2010. The Company reported a net loss of $1,045,043, or $0.06 per basic and diluted share, compared to a net loss of $3,031,201, or $0.22 per basic and diluted share, for the same period in 2009.

18 May 2010

Web conference to analyze latest trends, developments in the European melanoma skin cancer market

There are only two FDA/EMEA approved drugs currently available for treating advanced melanoma. The available drugs, however, are not completely effective and have adverse effects. Unmet needs of patients, especially those with advanced melanoma are therefore quite high and have led to a low drug adoption and market growth over the years. The future looks brighter though, with a few promising drugs in pipeline for advanced melanoma.

18 May 2010

Weikang Bio-Technology first-quarter revenue up 38.1% to record $14.0M

Weikang Bio-Technology Group Co., Inc., a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription pharmaceuticals and other health and nutritional products in the People's Republic of China, today announced its financial results for the first quarter of fiscal year 2010 ended on March 31, 2010.

18 May 2010

Columbia Laboratories renews license and supply agreement with Merck Serono

Columbia Laboratories, Inc. has renewed its license and supply agreement with Merck Serono, a division of Merck KGaA, Darmstadt, Germany, for CRINONE (progesterone gel) for an additional five-year term. Under the existing agreement and the renewal, Merck Serono has marketing rights worldwide, except the United States.

18 May 2010

KemPharm enters Supply Agreement with Johnson Matthey for KP201 hydrocodone prodrug for acute pain

KemPharm, Inc. today announced that it has entered into an exclusive Supply Agreement with Johnson Matthey Inc., for the manufacture of the active pharmaceutical ingredient (API), KP201, KemPharm's novel hydrocodone prodrug for acute pain. KP201 was identified utilizing KemPharm's proprietary ligand activated therapy (LAT) approach.

18 May 2010

Simcere Pharmaceutical first-quarter total revenue up 3.7% to $67.2 million

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today reported preliminary unaudited financial results for the quarter ended March 31, 2010.

18 May 2010

China Sky One Medical first-quarter total revenues increase 16.4% to $28.9 million

China Sky One Medical, Inc., a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China, today announced record financial results for the first quarter of 2010. Management is working diligently to finalize the amended Annual Report on Form 10-K for 2009.

18 May 2010

Pharmaceuticals News and Research

Vaccinations recommended for adults

i3 completes acquisition of ChinaGate

TPP raises £9.6M to develop early-stage pre-clinical drug candidates

New multi-center follow-up study of NX-1207 for treatment of BPH to be completed

Opinions: Gender-based violence and HIV; AIDS vaccine; Global NTDs; Responses to NYT HIV/AIDS articles

BMJ News examines how drug resistance, access undermine malaria fight in Uganda, Cambodia

Flibanserin benefits pre-menopausal women with Hypoactive Sexual Desire Disorder

Molecular Devices' foundational planar patch-clamp patent upheld by European Patent Office

PCMA releases statement on AARP's report on price increase in brand name prescriptions

RegeneRx Biopharmaceuticals prices underwritten public offering at $0.41 per unit

AARP: Cost of brand name drugs rose 9.7% last year

Report released on pharmaceutical mail-back pilot program funded by EPA

GCS to acquire FASA for $637 million

Catalyst Pharmaceutical Partners first-quarter net loss decreases to $0.06 per basic and diluted share

Web conference to analyze latest trends, developments in the European melanoma skin cancer market

Weikang Bio-Technology first-quarter revenue up 38.1% to record $14.0M

Columbia Laboratories renews license and supply agreement with Merck Serono

KemPharm enters Supply Agreement with Johnson Matthey for KP201 hydrocodone prodrug for acute pain

Simcere Pharmaceutical first-quarter total revenue up 3.7% to $67.2 million

China Sky One Medical first-quarter total revenues increase 16.4% to $28.9 million

Oxygen Measurement eBook - Easily Understand Dissolved Oxygen Measurement eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News